Abstract: The present invention includes 16-HETE analogs which are agonists and antagonists of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations. The invention also includes methods and products for inhibiting neutrophil adhesion and neutrophil aggregation using the 16-HETE agonists. One method of the invention involves the administration of a 16-HETE agonist in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke.
Type:
Grant
Filed:
November 9, 2001
Date of Patent:
May 13, 2003
Assignees:
Univ. Vermont and State Agricultural College, Univ. of Texas System Board of Regents, New York Medical College
Inventors:
John R. Falck, Martin M. Bednar, Cordell E. Gross, Michael Balazy
Abstract: Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.
Type:
Application
Filed:
January 16, 2002
Publication date:
December 26, 2002
Applicant:
Univ. of Texas System, Board of Regents
Inventors:
Darrell H. Carney, Roger S. Crowther, Janet Stiernberg, John Bergmann
Abstract: The present invention relates to a method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide and/or inhibiting or reducing vascular occlusion or restenosis. The invention also relates to methods of stimulating revascularization. In yet another embodiment, the invention relates to the use of thrombin derivative peptides in the manufacture of a medicament for the methods described herein.
Type:
Application
Filed:
January 16, 2002
Publication date:
December 12, 2002
Applicant:
Univ. of Texas System, Board of Regents
Abstract: Disclosed is a method of stimulating bone growth at a site in a subject in need of osteoinduction. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site.
Type:
Application
Filed:
January 16, 2002
Publication date:
December 5, 2002
Applicant:
Univ. of Texas System, Board of Regents
Inventors:
Darrell H. Carney, Roger S. Crowther, David J. Simmons, Jinping Yang, William R. Redin